

RECEIVED
CENTRAL FAX CENTER

MAR 04 2004

AstraZeneca Docket No. 100507-1

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

OFFICIAL

Application of: **PIERSON, et al.**
Application Number: **10/051,776**
Filed: **January 16, 2002**

Group Art Unit: **1624**
Examiner: **Patel, Sudhaker B**

For: **THERAPEUTIC HETEROCYCLIC COMPOUNDS**

Assistant Commissioner For Patents
Box Issue Fee
Washington, DC 20231

CORRESPONDENCE

Sir:

Applicants would like to bring to the examiner's attention that a Form 1449 mailed January 5, 2004 and received and date stamped at the PTO on January 7, 2004 was not included in the compilation of Information Disclosure Statements accompanying the applicant's notice of allowance. It is the applicants understanding that these references were considered prior to the notice of allowance being issued, as stated by the examiner on February 23, 2004. Therefore, applicants request an official copy of the signed Form 1449 for our records. Applicants have also enclosed a copy of the above referenced Form 1449 for the examiner's convenience.

CERTIFICATE OF FACSIMILE TRANSMISSION (37 C.F.R. § 1.8)

The undersigned hereby certifies that the attached papers and/or fee are being facsimile transmitted to the United States Patent and Trademark Office at the telephone number shown below on the date shown below.

Facsimile number: **1-302-886-8221**
Date: **March 4, 2004**

George Gilbert
Reg. No. 35,881

Signature

March 4, 2004

Respectfully Submitted

By 
George A. Gilbert
Attorney for Applicant
Reg. No. 35,881
Telephone: 302/886-3887

PTO/SB/08a (07-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1440A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary.)

Shoe

1

— 1 —

Complete If Known

Application Number	10/051,776
Filing Date	01/16/2002
First Named Inventor	Edward Pierson
Art Unit	1624
Examiner Name	

Attorney Docket Number 100507-1 US

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Cxtn ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 9109853	07/11/1991	Aktiebolaget Astra		
		EP 0546389	06/16/1993	Bayer AG		
		GB 2177084	01/14/1987	Imperial Chemical Industries		

**Executive
Signature**

Date
Considered

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.15 if possible. ⁶ Applicant is to place a check mark here if English language transcription is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

Approved for use through 07/31/2006. GMB 0851-R0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/051,776
				<i>Filing Date</i>	01/16/2002
				<i>First Named Inventor</i>	Edward Pierson
				<i>Art Unit</i>	1624
				<i>Examiner Name</i>	
<i>Sheet</i>	1	<i>of</i>	1	<i>Attorney Docket Number</i>	
100507-1 US					

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		PCT Written Opinion PCT/SE02/00070
		PCT Written Opinion PCT/SE02/00069
		PCT Written Opinion PCT/SE02/00068
		International Search Report for International Application No. PCT/SE02/00070
		International Search Report for International Application No. PCT/SE02/00069
		International Search Report for International Application No. PCT/SE02/00068 ✓

**Examiner
Signature**

Data Considered

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). **2** Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. Including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

AstraZeneca patent docket number A1573:
“galanin R2” and “galR2”

Pending applications: Canada, European Patent Office, and US

Issued patent: US (Patent Number US 6,562,945)

AstraZeneca patent docket number A1807:

“3B32” “DRR” “SNSR”

Pending applications: Canada, European Patent Office, Japan, and US

Issued patents: US (Patent Number 6,696,257); Australia (Patent number 756861)